[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645430":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":56,"collaborators":26,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":26,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":26,"enrollmentInfo":68,"targetDuration":26,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Tanta University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Febuxostat + standard medical treatment","EXPERIMENTAL","Patients will receive Febuxostat 40 mg once daily in addition to the standard medical treatment of conservatively managed intracranial hemorrhage for three months",[13,14],"Drug: Febuxostat 40 mg","Drug: Standard medical treatment",{"label":16,"type":17,"description":18,"interventionNames":19},"Standard medical treatment only","ACTIVE_COMPARATOR","Patients will receive only the standard medical treatment of conservatively managed intracranial hemorrhage for three months.",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Febuxostat 40 mg","Participants in this arm will receive Febuxostat at a dose of 40 mg orally once daily for a duration of three months, administered in addition to the standard traditional therapy for conservatively managed intracranial hemorrhage",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Standard medical treatment","Participants in this arm will receive only the standard traditional medical guidelines and therapy for conservatively managed intracranial hemorrhage for a duration of three months",[9,16],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Mertihan E Elhadidi","CONTACT","+201124955511","Merihanelhadidy9@gmail.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Neurosurgery department Mansoura university hospitals","RECRUITING","Al Mansurah","Dakahlia Governorate","35511","Egypt","EG",{"type":47,"coordinates":48},"Point",[49,50],31.38069,31.03637,{"lat":50,"lon":49},[53],{"name":54,"role":34,"phone":55,"phoneExt":26,"email":36},"Merihan Elhadidi Elhadidi, Clinical pharmacist","+201124955512",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Merihan Elhadidi Elhadidi","Clinical pharmacist","100645430","phase-2-clinical-study-to-evaluate-the-efficacy-of-febuxostat-in-the-treatment-of-conservatively-managed-intracranial-hemorrhage-patients-100645430",false,"NCT07701512","Clinical Study to Evaluate the Efficacy of Febuxostat in the Treatment of Conservatively Managed Intracranial Hemorrhage Patients","Inclusion Criteria:\n\n* • Age ≥ 18 years old.\n\n  * Diagnosed with intracranial hemorrhage confirmed by CT scan.\n  * Managed conservatively regarding clinical guidelines.\n  * Able to provide informed consent or have a legal representative provide consent.\n\nExclusion Criteria:\n\n* • Patients with a history of previous brain surgery or significant neurological disorders.\n\n  * Severe comorbidities (e.g., uncontrolled diabetes, severe cardiac disease).\n  * Allergy or contraindication to febuxostat.\n  * Pregnant or breastfeeding women.\n  * Patients requiring surgical intervention for hematoma evacuation.\n  * Renal impairment with SCr \\> 4\n  * Liver impairment with INR \\> 5\n  * Significant deterioration ( GCS \\\u003C 8 )","ALL","18 Years",{"count":69,"type":70},46,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","To assess the effect of Febuxostat on clinical outcomes and biomarkers of oxidative stress and inflammation in patients with conservatively managed intracranial hemorrhage.",[76],"Intracranial Hemorrhage",[78],"Intracranial hemorrhage","2026-07-14",{"date":81,"type":82},"2026-07-15","ACTUAL",{"date":84,"type":82},"2025-11-20",{"date":86,"type":70},"2027-01-30",{"name":5,"class":6},1]